Ignite Creation Date:
2024-05-05 @ 8:00 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00783536
Status:
WITHDRAWN
Last Update Posted:
2022-05-09
First Post:
2008-10-29
Brief Title:
A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
An Randomized Open Label Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate With DMARD Therapy in Subjects With Active Early Rheumatoid Arthritis
Status:
WITHDRAWN
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOTAR
Brief Summary:
This is a randomized open label active-comparator parallel design outpatient multicenter study being conducted in Mexico Subjects with early active Rheumatoid Arthritis RA who have not received treatment with a Disease-modifying antirheumatic drug DMARD in the previous 6 months will be eligible for the study Study subjects will be randomized into one of two treatments groups and receive either etanercept methotrexate or standard non-biologic DMARD therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None